1. Home
  2. Epicentre
  3. team
  4. Helena Huerga
Back to the list
Photo
Helena Huerga

Helena Huerga

Titre du poste
Medical epidemiologist
0000-0003-0302-9063
Contact by mail
Corps éditorial

 

Helena Huerga leads operational research studies with focus on infectious diseases and with particular interest on tuberculosis, HIV and viral hepatitis.  

Her publications

COVID-19, tuberculosis, and HIV triad: a prospective observational study in ambulatory patients in Kenya, Uganda, and South Africa.

Journal Reference: PLOS global public health 2025 ; 5(4); . doi: 10.1371/journal.pgph.0004471. Epub 2025 04 23

Adolescents and young adults are the most undiagnosed of HIV and virally unsuppressed in Eastern and Southern Africa: Pooled analyses from five population-based surveys.

Journal Reference: PLOS global public health 2023 ; 3(12); . doi: 10.1371/journal.pgph.0002398. Epub 2023 12 22

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.

Journal Reference: PLOS global public health 2023 ; 3(4); . doi: 10.1371/journal.pgph.0000818. Epub 2023 04 28

Evidence of HIV incidence reduction in young women, but not in adolescent girls, in KwaZulu-Natal, South Africa.

Journal Reference: IJID regions 2023 Sep ; 8; . doi: 10.1016/j.ijregi.2023.07.004. Epub 2023 07 13

Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study.

Journal Reference: The Lancet. Global health 2023 Jan ; 11(1); . doi: 10.1016/S2214-109X(22)00463-6. Epub 2022 12 19

Lots of considerations when evaluating the FujiLAM assay - Author's reply.

Journal Reference: The Lancet. Global health 2023 Apr ; 11(4); . doi: 10.1016/S2214-109X(23)00115-8. Epub 2023 03 16

Increase in HIV viral suppression in KwaZulu-Natal, South Africa: Community-based cross sectional surveys 2018 and 2013. What remains to be done?

Journal Reference: PloS one 2022 ; 17(3); . doi: 10.1371/journal.pone.0265488. Epub 2022 03 24

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs.

Journal Reference: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Mar 04; . doi: 10.1093/cid/ciac176. Epub 2022 03 04

Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort.

Journal Reference: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Jan 13; . doi: 10.1093/cid/ciac019. Epub 2022 01 13

Higher risk sexual behaviour is associated with unawareness of HIV-positivity and lack of viral suppression - implications for Treatment as Prevention.

Journal Reference: Scientific reports 2017 Nov 23; 7(1); 16117. doi: 10.1038/s41598-017-16382-6. Epub 2017 11 23

Population-level HIV incidence estimates using a combination of synthetic cohort and recency biomarker approaches in KwaZulu-Natal, South Africa.

Journal Reference: PloS one 2018 ; 13(9); e0203638. doi: 10.1371/journal.pone.0203638. Epub 2018 09 13

Integrating hepatitis C treatment into multidrug-resistant TB care.

Journal Reference: Public health action 2022 Jun 21; 12(2); . doi: 10.5588/pha.22.0002. Epub 2022 06 23

Incremental Yield of Including Determine-TB LAM Assay in Diagnostic Algorithms for Hospitalized and Ambulatory HIV-Positive Patients in Kenya.

Journal Reference: PloS one 2017 ; 12(1); e0170976. doi: 10.1371/journal.pone.0170976. Epub 2017 01 26

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.

Journal Reference: BMC infectious diseases 2019 Aug 20; 19(1); 733. doi: 10.1186/s12879-019-4378-4. Epub 2019 08 20

Prevalence of TB and health-seeking behaviour.

Journal Reference: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2022 May 01; 26(5); . doi: 10.5588/ijtld.22.0001. Epub 2022 05 05

Evidence of HIV incidence reduction in young women, but not in adolescent girls, in KwaZulu-Natal, South Africa.

Journal Reference: IJID regions 2023 Sep ; 8; . doi: 10.1016/j.ijregi.2023.07.004. Epub 2023 07 13

Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis.

Journal Reference: PloS one 2020 ; 15(1); e0227138. doi: 10.1371/journal.pone.0227138. Epub 2020 01 30

Progress towards the UNAIDS 90-90-90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa: a household-based community cross-sectional survey.

Journal Reference: BMC public health 2018 03 02; 18(1); 303. doi: 10.1186/s12889-018-5208-0. Epub 2018 03 02

Urine lipoarabinomannan (LAM) testing for all HIV patients hospitalized in the medical wards identifies a large proportion of patients with tuberculosis at risk of death.

Journal Reference: Open Forum Infectious Diseases; ofaa639; https://doi.org/10.1093/ofid/ofaa639; 23 December 2020

High prevalence of infection and low incidence of disease in child contacts of patients with drug-resistant tuberculosis: a prospective cohort study.

Journal Reference: Archives of disease in childhood 2018 Dec 06; . doi: 10.1136/archdischild-2018-315411. Epub 2018 12 06

Feasibility and acceptability of using the novel urine-based FujiLAM test to detect tuberculosis: A multi-country mixed-methods study.

Journal Reference: Journal of clinical tuberculosis and other mycobacterial diseases 2022 May ; 27; . doi: 10.1016/j.jctube.2022.100316. Epub 2022 04 25

Implementation and Operational Research: Feasibility of Using Tuberculin Skin Test Screening for Initiation of 36-Month Isoniazid Preventive Therapy in HIV-Infected Patients in Resource-Constrained Settings.

Journal Reference: Journal of acquired immune deficiency syndromes (1999) 2016 Apr 01; 71(4); e89-95. doi: 10.1097/QAI.0000000000000895. Epub 2016 07 06

Mortality in the first six months among HIV-positive and HIV-negative patients empirically treated for tuberculosis.

Journal Reference: BMC infectious diseases 2019 Feb 11; 19(1); 132. doi: 10.1186/s12879-019-3775-z. Epub 2019 02 11

Systematic, Point-of-Care Urine Lipoarabinomannan (Alere TB-LAM) Assay for Diagnosing Tuberculosis in Severely Immunocompromised HIV-Positive Ambulatory Patients.

Journal Reference: The American journal of tropical medicine and hygiene 2020 Jan 20; . doi: 10.4269/ajtmh.19-0493. Epub 2020 01 20

Increase in HIV viral suppression in KwaZulu-Natal, South Africa: Community-based cross sectional surveys 2018 and 2013. What remains to be done?

Journal Reference: PloS one 2022 ; 17(3); . doi: 10.1371/journal.pone.0265488. Epub 2022 03 24

A comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa.

Journal Reference: BMC infectious diseases 2017 09 29; 17(1); 653. doi: 10.1186/s12879-017-2740-y. Epub 2017 09 29

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs.

Journal Reference: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Mar 04; . doi: 10.1093/cid/ciac176. Epub 2022 03 04

Two-fold increase in the HIV viral load suppression rate along with decreased incidence over six years in Ndhiwa sub-county, Kenya.

Journal Reference: Tropical medicine & international health : TM & IH 2021 Oct 12; . doi: 10.1111/tmi.13688. Epub 2021 10 12

HIV epidemic and cascade of care in 12 east African rural fishing communities: results from a population-based survey in Uganda.

Journal Reference: BMC public health 2020 Jun 19; 20(1); 970. doi: 10.1186/s12889-020-09121-6. Epub 2020 06 19
See all